July 11, 2017 / 6:03 PM / 17 days ago

BRIEF-Cytovia Inc enters agreement with Pint Pharma for licensing of Ceplene in Latin America

1 Min Read

July 11 (Reuters) - Cytovia Inc :

* Cytovia Inc, Immune Pharmaceuticals’ oncology subsidiary, enters into a definitive agreement with Pint Pharma for the licensing and commercialization of Ceplene® in Latin America

* Cytovia Inc - Pint GMBH will separately enter into an investment agreement, which will lead to an investment of $4 million into Cytovia

* Cytovia Inc - ‍"Intend to immediately initiate regulatory registration of Ceplene in Latam markets based on European approval​"

* Cytovia - Massimo Radaelli, executive chairman of Pint, will also join board of co upon completion of investment, effective spin off of co from Immune Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below